Evaluation of serum omentin-1 and apelin concentrations in patients with hidradenitis suppurativa.
adipokines
apelin
hidradenitis suppurativa
omentin
Journal
Postepy dermatologii i alergologii
ISSN: 1642-395X
Titre abrégé: Postepy Dermatol Alergol
Pays: Poland
ID NLM: 101168357
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
07
01
2020
accepted:
20
01
2020
entrez:
11
8
2021
pubmed:
12
8
2021
medline:
12
8
2021
Statut:
ppublish
Résumé
Recent studies suggest a role of adipokines in the pathogenesis of hidradenitis suppurativa (HS). Omentin-1 and apelin are two recently identified adipokines that have been involved in the regulation of metabolic and inflammatory responses. To investigate serum omentin-1 and apelin levels in patients with HS and to assess their associations with metabolic parameters, disease severity and HS risk. This case-control study included 139 non-diabetic individuals (78 HS patients and 61 ageand sex-matched controls). Serum concentrations of omentin-1 and apelin and the homeostasis model assessment of insulin resistance (HOMA-IR) were measured in all participants. Serum omentin-1 concentrations were significantly higher in HS patients compared to controls, whereas apelin serum levels did not significantly differ between both groups. These differences in omentin-1 concentrations remained significant even after adjusting for age, sex, and body mass index (BMI). The results of logistic regression analysis showed that increased omentin-1 plasma levels were an independent risk factor for HS. However, we found no association between serum levels of both omentin-1 and apelin with HS severity. Our results show that patients with HS have raised omentin-1 serum levels, which are associated with HS risk.
Identifiants
pubmed: 34377127
doi: 10.5114/ada.2021.107932
pii: 107932
pmc: PMC8330847
doi:
Types de publication
Journal Article
Langues
eng
Pagination
450-454Informations de copyright
Copyright: © 2021 Termedia Sp. z o. o.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Sci Rep. 2018 Jul 30;8(1):11428
pubmed: 30061611
Clin Chim Acta. 2018 Aug;483:241-248
pubmed: 29750964
Endocrinology. 2005 Apr;146(4):1764-71
pubmed: 15677759
J Am Coll Nutr. 2016 Nov-Dec;35(8):670-678
pubmed: 27331575
Scand J Gastroenterol. 2011 Jan;46(1):91-7
pubmed: 20809771
J Eur Acad Dermatol Venereol. 2019 Nov;33(11):2131-2136
pubmed: 31260574
Clin Exp Rheumatol. 2011 Nov-Dec;29(6):1044-8
pubmed: 22032341
J Invest Dermatol. 2019 Jun;139(6):1294-1305
pubmed: 30528824
Clin Exp Dermatol. 2019 Jun;44(4):e126-e132
pubmed: 30730068
Diabetes Metab Res Rev. 2019 Jan;35(1):e3074
pubmed: 30198166
Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1253-61
pubmed: 16531507
Dermatoendocrinol. 2010 Jan;2(1):9-16
pubmed: 21547142
Mediators Inflamm. 2012;2012:347268
pubmed: 22927708
Circulation. 2002 Dec 17;106(25):3143-421
pubmed: 12485966
Br J Dermatol. 2018 Mar;178(3):792-793
pubmed: 28834543
Int J Dermatol. 2019 Oct;58(10):1112-1117
pubmed: 31148159
J Eur Acad Dermatol Venereol. 2015 Apr;29(4):619-44
pubmed: 25640693
PLoS One. 2012;7(10):e46740
pubmed: 23144698
Diabetes. 2007 Jun;56(6):1655-61
pubmed: 17329619
J Eur Acad Dermatol Venereol. 2018 May;32(5):820-824
pubmed: 29485215
J Interferon Cytokine Res. 2018 Dec;38(12):527-538
pubmed: 30431386
J Am Acad Dermatol. 2016 Aug;75(2):329-35
pubmed: 27287248
Diabetes Metab Syndr Obes. 2019 Jul 31;12:1277-1286
pubmed: 31447571
Australas J Dermatol. 2018 Nov;59(4):267-277
pubmed: 29355905
Arch Dermatol Res. 2018 Dec;310(10):785-793
pubmed: 30293125
Front Immunol. 2018 Dec 14;9:2965
pubmed: 30619323
Arch Dermatol Res. 2020 Oct;312(8):595-600
pubmed: 31786710
J Am Acad Dermatol. 2014 Dec;71(6):1144-50
pubmed: 25440440
Expert Rev Clin Immunol. 2018 Apr;14(4):275-283
pubmed: 29509041
G Ital Dermatol Venereol. 2020 Oct;155(5):646-651
pubmed: 29747483